Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meningococcal polysaccharide (serogroups A, C, W, and Y) tetanus toxoid conjugate vaccine
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Meningococcal polysaccharide (serogroups A, C, W, and Y) tetanus toxoid conjugate vaccine is an active immunizing agent used to prevent invasive disease caused by Neisseria meningitidis serogroups A, C, W, and Y. The vaccine contains purified capsular polysaccharides from these four serogroups of N. meningitidis individually conjugated to a carrier protein—tetanus toxoid—which enhances the immune response by promoting T-cell dependent immunity. This results in the production of protective antibodies against the targeted serogroups. It does not protect against other groups such as group B. The primary indication is prevention of invasive meningococcal disease including conditions like bacterial meningitis and septicemia[1][4][5][8]. Major developers include Sanofi (MenQuadfi), GlaxoSmithKline (Menveo), and previously Sanofi for Menactra.
- Brand names
- MenQuadfiMenveoMenactra
- Other names
- meningococcal conjugate vaccinemeningococcal vaccine, tetanus toxoid conjugate quadrivalentmeningococcal (groups A, C, W, Y) polysaccharide tetanus toxoid conjugate vaccine
02
Targets
Neuraminidase
Beyond the preview
Go deeper on Meningococcal polysaccharide (serogroups A, C, W, and Y) tetanus toxoid conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meningococcal polysaccharide (serogroups A, C, W, and Y) tetanus toxoid conjugate vaccine.